Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Argus Health
Fuji
Covington
Federal Trade Commission
Queensland Health
QuintilesIMS
Teva
McKinsey

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040195

« Back to Dashboard

NDA 040195 describes ACETAZOLAMIDE, which is a drug marketed by Heritage Pharms Inc, Nostrum Labs Inc, Novast Labs Ltd, Zydus Pharms Usa Inc, Alra, Ascot, Heritage Pharma, Lannett, Strides Pharma, Sun Pharm Industries, Taro, Vangard, Watson Labs, Hospira, Mylan Asi, Par Sterile Products, West-ward Pharms Int, X Gen Pharms, and Emcure Pharms Ltd, and is included in twenty NDAs. It is available from fifteen suppliers. Additional details are available on the ACETAZOLAMIDE profile page.

The generic ingredient in ACETAZOLAMIDE is acetazolamide sodium. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the acetazolamide sodium profile page.
Summary for 040195
Tradename:ACETAZOLAMIDE
Applicant:Taro
Ingredient:acetazolamide
Patents:0
Therapeutic Class:Ophthalmic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 040195
Ingredient-typeSulfonamides
Mechanism of ActionCarbonic Anhydrase Inhibitors
Medical Subject Heading (MeSH) Categories for 040195
Suppliers and Packaging for NDA: 040195
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACETAZOLAMIDE acetazolamide TABLET;ORAL 040195 ANDA NCS HealthCare of KY, Inc dba Vangard Labs 0615-1511 N 0615-1511-39
ACETAZOLAMIDE acetazolamide TABLET;ORAL 040195 ANDA A-S Medication Solutions 50090-0279 N 50090-0279-0

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength125MG
Approval Date:May 28, 1997TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:May 28, 1997TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Federal Trade Commission
Moodys
Dow
UBS
Teva
QuintilesIMS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.